Stephens Inc. AR Sells 15,654 Shares of Boston Scientific Co. (NYSE:BSX)

Stephens Inc. AR trimmed its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 60.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,398 shares of the medical equipment provider's stock after selling 15,654 shares during the period. Stephens Inc. AR's holdings in Boston Scientific were worth $871,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of BSX. Eagle Bay Advisors LLC raised its stake in shares of Boston Scientific by 542.1% in the 1st quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider's stock worth $25,000 after buying an additional 309 shares in the last quarter. First Foundation Advisors bought a new stake in Boston Scientific in the first quarter worth about $25,000. Triad Wealth Partners LLC acquired a new stake in Boston Scientific in the 2nd quarter valued at about $26,000. Values First Advisors Inc. acquired a new stake in Boston Scientific in the 3rd quarter valued at about $28,000. Finally, Andra AP fonden bought a new position in shares of Boston Scientific during the 2nd quarter valued at about $29,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the business's stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the transaction, the executive vice president now directly owns 160,467 shares in the company, valued at $13,639,695. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CEO Michael F. Mahoney sold 162,777 shares of the company's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the transaction, the chief executive officer now owns 1,572,096 shares in the company, valued at $133,046,484.48. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph Michael Fitzgerald sold 132,527 shares of the business's stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the completion of the transaction, the executive vice president now directly owns 160,467 shares of the company's stock, valued at approximately $13,639,695. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 309,270 shares of company stock valued at $26,196,718. 0.50% of the stock is owned by insiders.

Boston Scientific Stock Up 1.1 %

Shares of BSX traded up $0.90 during trading hours on Wednesday, hitting $86.44. 6,168,488 shares of the company were exchanged, compared to its average volume of 6,101,646. The firm's 50 day moving average is $84.21 and its 200-day moving average is $78.68. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.61. Boston Scientific Co. has a 52 week low of $50.84 and a 52 week high of $88.79. The company has a market cap of $127.29 billion, a PE ratio of 70.69, a PEG ratio of 2.46 and a beta of 0.79.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.59 by $0.04. The company had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.41%. The company's quarterly revenue was up 19.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.50 earnings per share. On average, equities research analysts forecast that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on BSX shares. JPMorgan Chase & Co. increased their target price on shares of Boston Scientific from $82.00 to $85.00 and gave the company an "overweight" rating in a research note on Thursday, July 25th. Morgan Stanley increased their price objective on Boston Scientific from $92.00 to $100.00 and gave the company an "overweight" rating in a research report on Thursday, October 24th. Barclays boosted their target price on Boston Scientific from $78.00 to $86.00 and gave the stock an "overweight" rating in a research report on Thursday, August 22nd. Robert W. Baird increased their price target on Boston Scientific from $90.00 to $91.00 and gave the company an "outperform" rating in a research report on Thursday, July 25th. Finally, Needham & Company LLC restated a "hold" rating on shares of Boston Scientific in a report on Thursday, October 31st. Four research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $93.39.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.